Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand-Reference-Cited by-同舟云学术

Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand

Author:

D’Angelo Alberto¹^ORCID,Bagby Stefan¹,Galli Ilaria Camilla²,Bortoletti Carlotta³,Roviello Giandomenico⁴

Affiliation:

1. Department of Biology and Biochemistry, University of Bath, Bath, UK

2. Department of Health Sciences, University of Florence, Section of Pathological Anatomy, University Hospital of Florence, Florence, Italy

3. Department of Dermatology, University of Padova, Padova, Italy

4. Department of Health Sciences, University of Florence, Florence, Italy

Funder

not receive any funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

Reference63 articles.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

4. Authors’ reply to Nandi;Cancer Research, Statistics, and Treatment;2023